Idh-mutant Glioma
📧 Sign up to get email alerts when something new happens for Idh-mutant Glioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
A clinical trial update describing a study in low-grade gliomas evaluating patient-reported outcomes with vorasidenib in combination with ra…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Window of Opportunity Study of DSP-0390 in Gliomas [EARLY_Phase 1]
An early-phase 1 window-of-opportunity trial of DSP-0390 in malignant gliomas with IDH mutation is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas [Phase 1]
A Phase 1 study of ASTX727 is recruiting for recurrent/progressive non-enhancing IDH-mutant gliomas. The trial investigates the oral decitab…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors [NA]
Observational study in recurrent central nervous system tumors to evaluate responses to various treatments in brain tumors, with ongoing rec…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas [NA]
A completed trial evaluating temporally-modulated pulsed radiation therapy after prior EBRT in adults with recurrent IDH-mutant gliomas, inc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma [Phase 2]
Phase 2 clinical trial assessing the combination of All-Trans Retinoic Acid (ATRA) with a PD-1 inhibitor in recurrent IDH-mutant glioma; rec…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Niraparib In Recurrent IDH 1/2 Gliomas [EARLY_Phase 1]
An early-phase 1 trial update evaluating niraparib in recurrent IDH1/2-mutant gliomas, including low-grade and malignant gliomas.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma [EARLY_Phase 1]
Early-phase clinical trial investigating hyperpolarized carbon-13 alpha-ketoglutarate imaging in IDH-mutant glioma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation [Phase 3]
A Phase 3 trial evaluating vorasidenib for Asian participants with residual or recurrent grade 2 IDH-mutant glioma is currently active but n…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Recurrent or Progressive IDH Mutant Gliomas [Phase 2]
Phase 2 trial of nivolumab for recurrent or progressive IDH-mutant gliomas has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Olaparib in Recurrent IDH-mutant Glioma [Phase 2]
Phase 2 trial of olaparib in recurrent IDH-mutant glioma has been completed.
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
APPEAR is a clinical trial evaluating amino acid PET-based response assessment in IDH-mutant gliomas and is currently recruiting, sponsored …
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: Study of Olutasidenib and Temozolomide in HGG [Phase 2]
Phase 2 study evaluating olutasidenib in combination with temozolomide for high-grade gliomas is currently recruiting.